An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial

Andrew Grigg,Belinda Butcher,Bereha Khodr,Ashish Bajel,Mark P. Hertzberg,Sushrut Patil,Alwyn D'Souza,Peter Ganly,Peter R. Ebeling,Eric Wong

An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial

2017

Andrew Grigg
Belinda Butcher
Bereha Khodr
Ashish Bajel
Mark P. Hertzberg
Sushrut Patil
Alwyn D'Souza
Peter Ganly
Peter R. Ebeling
Eric Wong

An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial

Keywords:

Oncology
Diabetes mellitus
Immunology
Transplantation
Medicine
Stem cell
Zoledronic acid
Internal medicine
Surgery
Femoral neck
Prospective cohort study
Bone density
Phases of clinical research
Hematopoietic stem cell transplantation
Transplantation Conditioning

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations